Kornimate/medical-research-clean huggingface dataset:
observatory of prolymphocytic leukemia t

Conditions: Prolymphocytic Leukemia; T-cell Leukemia

Summary: prolymphocytic leukemia t is a rare disease representing approximately 2% of mature lymphoid leukemias and 20% of prolymphocytic leukemias. it mainly affects the elderly with an aggressive clinical course. it is a hemopathy exhibiting a post thymic t phenotype (tdt-, cd1a-, cd5 +, cd2 + and cd7 +), generally cd4 + / cd8-, but also cd4 + / cd8 + or cd8 + / cd4-. the main feature of t-pll is the rearrangement of chromosome 14 involving genes encoding the t cell receptor complex (tcr) subunits, leading to overexpression of the proto-oncogene tcl1. on the molecular level, the study of prolymphocytic leukemia t shows a substantial mutational activation of the il2rg-jak1-jak3-stat5b axis. patients with prolymphocytic leukemia t have a poor prognosis, due to a poor response to conventional chemotherapy. treatment with the anti-cd52 monoclonal antibody: alemtuzumab has considerably improved the results, but the responses to treatment are transient; therefore, patients who obtain a response to alemtuzumab treatment are candidates for stem cell allograft (tss) if they are eligible for this procedure. this combined approach extended the median survival to four years or more. however, new approaches using well-tolerated therapies that target signaling and survival pathways are necessary for most patients who are unable to receive intensive chemotherapy, such as jak stat axis inhibitors, anti-akt, or anti bcl2 . main objective: better manage prolymphocytic t leukemias. secondary objectives: * molecular characterization of prolymphocytic leukemia t. * study of the response to treatment, disease-free survival, overall survival. * impact of prognostic factors on response to treatment, and survival.


Eligibility criteria:
inclusion criteria: * man or woman aged 18 or over * patient with prolymphocytic t leukemia exclusion criteria: * absence of signature of informed consent
ultrasound-guided neuromodulation percutaneous

Conditions: Low Back Pain

Summary: chronic low back pain (lbp) is one of the most familiar musculoskeletal pains and alone has been the main origin of years lived with disability for the past three decades. lbp is identified as a nonspecific, painful or mechanical situation in the lower back, buttocks, or hips. although an underlying origin in chronic lbp has been proposed to be due to a multitude of factors, a muscle hip disbalance has been recognized5. a limited hip internal rotation range of motion (ir-rom) and hip abductor weakness were found in patients with lbp symptoms7 in the field of physiotherapy, ultrasound-guided percutaneous neuromodulation (pnm) is defined as the application through a needle with ultrasound guidance of an electrical current at low or medium frequency, seeking a sensitive and / or motor response of a peripheral nerve in some point of its trajectory, or of a muscle in a motor point, with a therapeutic objective. however, authors hypothesize that neuromodulation (especially the us-guided pnm technique) may be used to obtain more therapeutic effects, including pain relief. the main aim of this study was to investigate the effect of hip muscle strengthening by a simple single-shot procedure with the us-guided pnm technique in people with lbp. a second purpose was to discover if the stimulation point in the sciatic nerve territory may influence the change of strength in these patients sixty subjects will be recruited, which will be divided into 3 groups: group 1 to which pnm will be applied to the sciatic nerve in the gluteus region; group 2 to which pnm will be applied to the sciatic nerve in the middle of the thigh; and group 3 to which pnm will be applied to the sciatic nerve before popliteus region. the pnm intervention with nmp will consist in the single application of an asymmetric rectangular biphasic current (250 microseconds, 3 hz) during 90 seconds


Eligibility criteria:
inclusion criteria: * diagnosis of lower back pain * having no other therapy exclusion criteria: * other pathology (discal hernia, injured limbs, neurological pathology) * belenophobia
computer-assisted diagnosis system based on linked colour imaging

Conditions: Colorectal Polyp; Linked Color Imaging; Computer-aided Diagnosis

Summary: linked color imaging (lci)，a new endoscopy modality, creates clear and bright images by using short wavelength narrow band laser light. lci can make red area appear redder and white areas appear whiter. thus, it may be possible to distinguish adenoma and non-adenoma polyps based on color evaluation of lci images. this study aimed to assess the correlation between histology results and lci images. moreover, the investigators conducted a pilot study to explore the clinical potential of lci to distinguish adenoma and non-adenoma polyps and the accuracy of an automatic computer-aided diagnosis system using lci imagine to predict histology polyps when compared to human experts physicians.

this study consists of a retrospective analysis and a pilot study. in the retrospective study, the investigators tried to find out an correlation between lci images and histology results for polyp lesions. and a computer-aided analysis of the images was conducted to demonstrate the correlation objectively. thereafter,a pilot study was performed to explore whether the previous correlation could be easily learned to distinguish adenoma and non-adenoma polyps by comparing the results of experts diagnosis of lci image and non-experts. also, in the pilot study, the investigators assessed the accuracy of an automate histology diagnosis method for polyp lci images using the computer-aided system when compared to human experts physicians. throughout the entire research, histology results are regarded as gold standard.

Eligibility criteria:
inclusion criteria: - at least one polyp found during colonoscopy examination. exclusion criteria: - poor quality of bowel preparation which impedes histology evaluation; previous resection of colon; inflammatory bowel disease; familiar adenomatous polyposis; peutz-jeghers syndrome or other polyposis syndrome.
family therapy for adolescent bulimia nervosa

Conditions: Bulimia Nervosa

Summary: the primary hypotheses are: * a procedurally distinct family therapy is an effective and essential way to reduce bingeing and purging in adolescents with bn, and leads to the long-term amelioration of bulimic symptoms. * family therapy is an effective way to bring about meaningful improvements in family interaction. * family therapy will produce significantly larger reductions in bulimic symptoms and improved family interaction in adolescents with bn compared to a control supportive psychotherapy.

bulimia nervosa (bn) is a disabling eating disorder and affects as many as 2% of young women. it is a major source of psychiatric and medical morbidity that often impairs several areas of functioning. even more alarming is the fact that bn is occurring with increasing frequency among adolescents and preadolescents. applying stringent diagnostic criteria for bn, studies have found 2-5% of adolescent girls surveyed qualify for diagnosis of bn. research specific to treatment of child and adolescent eating disorders remains limited. no psychological treatment has been systematically evaluated in the treatment of adolescents with bn. however, a series of studies from the maudsley hospital in london have shown that family therapy (the 'maudsley approach') is effective in the treatment of adolescents with anorexia nervosa (an). these studies have shown that involving the parents and siblings in treatment has beneficial effects on reversing the course of the eating disorder as well as improving family interaction. a preliminary report from the maudsley group has also shown that the 'maudsley approach' may be helpful in the treatment of adolescents with bn. because most young adolescents still live with their families of origin, this raises the interesting clinical question that adolescent bn patients can also be successfully treated with family therapy. the proposed study has two specific aims: 1. to adapt and pilot a recently developed family therapy manual for adolescent an for use in the treatment of adolescent bn patients. 2. to compare the efficacy of this conceptually and procedurally distinct family therapy treatment with individual control psychotherapy. to achieve these aims, we propose a five-year controlled treatment study to be carried out at the university of chicago. eighty newly referred adolescent patients meeting dsm-iv diagnostic criteria for bn will be randomly allocated to one of two groups: 1) family therapy or 2) the individual supportive control treatment. all patients will receive the same medical evaluation and monitoring throughout the study period. assessment of psychiatric and medical outcome measures will be carried out at the onset of treatment, during treatment, at the end of treatment, and again at one-year follow-up. the clinical outcome variables assessed will include the ede, ksads, rse, and ee.

Eligibility criteria:
inclusion criteria: * dsm-iv criteria for bulimia nervosa or partial bulimia nervosa exclusion criteria: * psychotic illness acute suicidality medical illness that impacts weight pregnant

Keywords: binge eating purging
curb, alter, lower, or manage stress in hiv: calms-hiv

Conditions: HIV Infections

Summary: the purpose of this study is to determine the effectiveness of a stress management group intervention for people with hiv. the study will evaluate several outcomes, including perceived stress, quality of life, psychosocial factors, and physiological measures of stress.

it is well documented that living with hiv/aids can cause a great amount of stress, and evidence suggests that stress may hasten hiv disease progression by increasing viral replication and suppressing the immune response. stress management intervention studies using more complex combinations of cognitive and relaxation therapies have shown improvements in both psychological and physiological measures in hiv infected persons. however, no studies have focused on only one intervention or have addressed the spiritual component using a comparable control group to determine which of these interventions is most effective. participants will be randomly assigned to receive either a spiritually-based cognitive intervention to an educational control group. the intervention will be given over a 10-week period, with 5 weekly classes, 4 weekly automated phone calls, and one final class meeting. assessments will be conducted at pre-intervention, fifth class midpoint, tenth week post-intervention, and 3-month follow-up. time commitment can vary from 6 months to 9 months, depending on when participants are screened.

Eligibility criteria:
inclusion criteria: * hiv infected for at least 6 months * ability to read and write english exclusion criteria: * drug use within the past 6 months * cognitive impairment or dementia * diagnosis that may affect cortisol levels, such as diabetes, cancer, or asthma * loss of family/loved one in past 3 months * started a relaxation therapy in past 3 months * history or current practice of the rise program, rosary, chanting, or transcendental meditation (tm) * acute infection in past month * change of haart or drug regimen in past month

Keywords: hiv randomized trial stress spirituality quality of life complementary therapies
dc vaccination for post-remission therapy in aml

Conditions: Acute Myeloid Leukemia

Summary: this is a multi-centre, open label, prospective, non-randomized phase i/ii trial in 20 patients including a safety-run in phase i part comprising 6 patients. trial subjects will receive repeated immunotherapies with autologous dendritic cells (dcs), presenting two leukemia-associated antigens.

20 patients with aml who are in remission (eln criteria by döhner et al 2017) receive wt1/prame autologous dc vaccine by intradermal injection once per week during the first 4 weeks and 1 per month thereafter for 23 consecutive months. primary objective is to assess the safety and tolerability of the dc vaccine in the aforementioned population and the feasibility. secondary objectives include evaluation of clinical response and exploratory immune monitoring assessments.

Eligibility criteria:
inclusion criteria: * diagnosis of acute myeloid leukemia (aml) * age 18 - 75 years * morphologic remission (cr) with or without hematological recovery (cri) following induction chemotherapy * wt1 with or without prame positivity by qpcr * negative pregnancy test in women of childbearing potential (within 7 days before the first vaccination). women of childbearing potential and sexually active male participants must use reliable methods of contraception during the whole treatment period and 3 months after the last trial drug dose * negative hiv 1 and 2 test, hepatitis b and c test and negative syphilis test at screening * informed consent signed prior to any trial related activities exclusion criteria: * patients suitable for allogeneic stem cell transplantation * aml m3 (acute promyelocytic leukemia) * patients not in complete remission (cr or cri), bone marrow blast count ≥ 5 % * active immunodeficiency syndromes * concurrent active second malignancy other than non-melanoma skin cancers * clinically relevant autoimmune disease * prior immunotherapy * severe organ dysfunction precluding the apheresis procedure: * creatinine \> 200 mmol/l * bilirubin, alat and asat \> 3 x upper normal limit * respiratory insufficiency with po2 \< 60 mmhg * clinically relevant coronary heart disease of ventricular arrhythmia, congestive heart failure \> grade ii nyha * recent cerebral hemorrhage * known allergies to substances used in the generation of dcs * other severe acute or chronic medical psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or the administration of the investigational product * use of corticosteroids * active cmv infection (antibody-positivity due to previous, now inactive infection is accepted) * inability to comply with the trial protocol * participation in other clinical trials that, according to the investigator's discretion, may interfere with this trial

Keywords: aml
bil. lr rec. using standard tables vs reduced numbers in intermittent exo. in children under 6

Conditions: Alternating Exotropia

Summary: comparing the motor alignment and the incidence of postoperative esotropia following the correction of intermittent exotropia in children below 7 years by bilateral lateral rectus recession using the standard recession tables postulated by parks versus correction using a reduced recession by one millimeter


Eligibility criteria:
inclusion criteria: * patients with poor control intermittent exotropia (where poor control is defined as having a newcastle score of 3 or more). (9) * basic, pseudo- divergence excess and divergence excess types are included. * if associated with amblyopia it should be corrected before the surgical correction (where the visual acuity will be assessed by the single crowded hotv test using a commercial projector). exclusion criteria: * intermittent exotropia of the convergence insufficiency type. * intermittent exotropia with angle of deviation greater than 50 prism diopters. * patients with previous squint surgery. * patients with secondary deviation due to a sensory lesion or neurological condition.
clinical evaluation of the surgisis biodesign vesico-vaginal fistula plug

Conditions: Vesico-vaginal Fistula

Summary: this clinical trial will study the safety and effectiveness of the biodesign vesico-vaginal fistula plug in the treatment of vesico-vaginal fistulas resulting from childbirth trauma.


Eligibility criteria:
inclusion criteria: * patient has signed and dated the informed consent. * patient is 18 years old; or is an emancipated minor as defined by ugandan law or is under 18 but has a parent/guardian who provides informed consent. * patient agrees to follow-up schedule. * patient presents with a leaking vesico-vaginal fistula, confirmed by exam, with no signs of acute inflammation, no signs of active urinary tract infection that cannot be controlled with a standard pre-operative course of antibiotics, no signs of vaginal infection, or no signs of abscess. * patient presents with a fistula of a size and in a location that may be reasonably treated with the vvp device. exclusion criteria: * patient is not medically fit enough for surgery under general or spinal anesthesia. * patient is a "mature minor" as defined by ugandan law. * patient is pregnant, breastfeeding or planning further pregnancy during the study period. * patient has physical allergies or cultural objections to the receipt of porcine products. * patient has an active sexually transmitted disease, is hiv-positive, or any other active systemic infection that may interfere with healing. * patient has spina bifida or other neural tube defect. * patient has interstitial cystitis or other chronic pelvic pain syndrome. * patient has signs of acute or chronic pelvic inflammation, active urinary tract infection not responsive to antibiotic treatment, vaginal infection, or abscess of the fistula tract. * patient presents with clinically diagnosed sepsis (for whatever reason). * patient has concomitant ureterovaginal fistula.

Keywords: fistula vesico-vaginal fistula
learning to breathe: a randomized controlled trial to lower diabetes risk in adolescent girls

Conditions: Type 2 Diabetes; Depression; Obesity

Summary: type 2 diabetes is a chronic disease that puts people at risk for major health problems like heart disease. type 2 diabetes is the most common type of diabetes in adults. however, there has been a concerning rise in type 2 diabetes among teenagers. diabetes develops through poor insulin sensitivity, meaning that insulin - an important chemical the body makes to keep blood sugar normal - isn't working properly. type 2 diabetes can be prevented by improving insulin sensitivity. stress is related to insulin sensitivity. individuals who feel stressed have worse insulin sensitivity than individuals who do not feel stressed. in adults, decreasing stress leads to improvements in insulin sensitivity, but this hasn't been tested in teenagers. the purpose of this study is to find out if taking part in a brief group program to decrease stress will improve insulin sensitivity and lower diabetes risk in teenage girls.

after a screening to determine eligibility, girls are randomly assigned to take part in one of two 6-week group programs: 1) learning to breathe - a mindfulness-based program, or 2) colorado blues - a cognitive-behavioral program. after the group, girls return for three follow-up visits over the course of a year. the main outcomes are depressive symptoms and insulin resistance. we also are assessing stress, eating behavior, fitness, and mindfulness.

Eligibility criteria:
inclusion criteria: * age 12-17 years * female * overweight or obese, defined as a body mass index (bmi; kg/m2) ≥ 85th percentile for age * family history of type 2 diabetes or pre-diabetes in 1st degree relative (e.g., parent or sibling) or 2nd degree relative (e.g., aunt, uncle, or grandparent) * elevated stress/symptoms of depression as indicated by a center for epidemiological studies-depression scale total score ≥ 16 * good general health as reported by adolescent and parent/guardian * english speaking (required for adolescent only, because the groups will be conducted in english) exclusion criteria: * pregnancy * current psychiatric disorder such as major depressive disorder necessitating treatment * type 2 diabetes as indicated by fasting glucose \> 126 mg/dl * use of medication affecting insulin resistance, body weight, or mood such as anti-depressants or stimulants * current psychotherapy or weight loss treatment

Keywords: adolescent diabetes depression obesity stress
inflammation and co-infections in d²eft

Conditions: HIV-infection/Aids; Human Herpesvirus 4 Infections; Cytomegalovirus Infections; Human Herpesvirus 8 Infection; Human Papilloma Virus

Summary: i2-d²eft substudy is an observational cohort nested within the parent d²eft study (nct03017872). d²eft goal is to compare the standard of care second-line antiretroviral therapy in people living with hiv whose first-line non nucleoside reverse transcriptase-based regimen failed, to two simpler regimens. approximately 1,000 participants will be enrolled in d²eft. commencing a second-line art is an important moment when the level of inflammation in participants may be elevated due to first-line art failure; this level of inflammation should then decrease with the commencement of a new second-line treatment and would be expected to normalise by 48 weeks of second-line treatment, if successful. the investigators propose to study other factors which can influence the decrease of inflammation. the investigators hypothesise that co-infections may play a role in persistent inflammation. the key-infections of interest will be common frequent infections encounter throughout the world: human herpes virus 8, epstein-barr virus, cytomegalovirus and human papillomavirus, tuberculosis, malaria and other key opportunistic infections. possible changes of level of inflammation (using the serum level of interleukin 6) in approximately 200 participants of the d²eft study will be investigated and measured. the hypothesis is that the presence of other infections than hiv may influence the level of inflammation in participants in therapeutic success.

i2-d²eft substudy an observational cohort nested within the parent open label phase iii/iv randomised controlled trial of simplified second-line therapy, d²eft (nct03017872). participants consenting to d²eft study will be randomised within the three arms: either ritonavir-boosted darunavir plus two nucleosides or dolutegravir plus two predetermined nucleosides (tenofovir disoproxil fumarate plus lamivudine or emtricitabine) or ritonavir-boosted darunavir plus dolutegravir. enrolment into the i2-d²eft substudy is voluntary and optional for participants in d²eft. parameters relevant to i2-d²eft substudy including demographics, arm of randomised art, hiv history, physical examination, immunological and virological results, episodes of co-infections and adverse events due to any infection or malignancies at required time points will be collected as part of d²eft study. substudy specific assessments performed at baseline and at weeks 48 include sample collection for il-6 dosage plus ebv/cmv/hhv8 testing, and optional anal/cervical hpv screening.

Eligibility criteria:
inclusion criteria: * fulfil the eligibility criteria for d²eft randomisation; * being able to give a written informed consent for the i2-d²eft sub-study. exclusion criteria: * unwilling to comply with the i2-d²eft protocol requirements.

Keywords: hiv il-6 ebv cmv hhv8 hpv inflammation co-infections opportunistic infections aids and non-aids defining cancers